In the video above, Parker Waichman attorney Gerard Ryan discusses the dangers of combining Tekturna (aliskiren) with other types of blood pressure medications, particularly ACE inhibitors and ARBs. Tekturna, also sold as Rasilez outside of the United States, is a hypertension drug manufactured by Novartis. Over the past year, it has raised health concerns over reports that may to lead to complications such as stroke and kidney problems. Last year, Novartis stopped clinical trials with Tekturna due to instances of non-fatal stroke, renal complications, hyperkalemia (high potassium) and hypotension (low blood pressure).
In April, the U.S. Food and Drug Administration (FDA) updated the label on Tekturna to warn against using the drug in patients with diabetes or moderate renal impairment (GFR<60 mL/min) taking ACE inhibitors or ARBs. A recent study published in the New England Journal of Medicine found that Tekturna was associated with more cardiac and renal complications compared to ACE inhibitors or ARBs. The authors concluded that combining Tekturna with these medications is not recommended, and may be harmful.